Japan Startup Tests Catheter Injection of iPS Heart Muscle Cells

Tokyo, June 13 (Jiji Press)--Japanese startup Heartseed Inc. has said it conducted a clinical trial to inject via catheter small masses of heart muscle cells produced from induced pluripotent stem, or iPS, cells into patients with severe heart failure. The Tokyo-based company,

Raccontata damorningstar.comasahi.comadnkronos.com